Ads
related to: Enbrel- Is RINVOQ Right For You?
RINVOQ® Could Be Right For You.
See RINVOQ® Clinical Trial Results.
- What Is RINVOQ®?
Learn About The FDA-Approved
Oral Pill.
- Watch Video
What Is RINVOQ®?
Watch A Video To Learn More.
- Register For More Info
Sign Up For More
Information About RINVOQ®.
- Treatment Didn't Help?
Looking To Change Treatments?
RINVOQ® Could Be The Right Fit.
- Talk With Your Doctor
Get Talking Tips To Guide
Conversation With Your Doctor.
- Is RINVOQ Right For You?
Search results
Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts
Investor's Business Daily· 2 years agoAmgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter...
Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 1 year agoAmgen AMGN reported first-quarter 2023 earnings of $3.98 per share, which beat the Zacks Consensus...
Here's How Much a $1000 Investment in Amgen Made 10 Years Ago Would Be Worth Today
Zacks via Yahoo Finance· 5 months agoHow much a stock's price changes over time is a significant driver for most investors. Not only can...
Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down
Zacks via Yahoo Finance· 1 year agoPfizer PFE reported fourth-quarter 2022 adjusted earnings per share of $1.14, which significantly...
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoPfizer PFE will report third-quarter 2022 results on Nov 1, before market open. In the last reported...
Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for Amgen (AMGN). Shares have lost about...
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 3 months agoFor more than a century, American investors have looked to the Dow Jones Industrial Average...
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx
Investor's Business Daily· 2 years agoAmgen stock dipped Friday after the company narrowed its 2022 outlook and announced its $3.7 billion...
The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List
Investor's Business Daily· 9 months agoThere's a piece of bad news for Novo Nordisk's massively popular diabetes drug Ozempic in Medicare's...
FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - source
Reuters via Yahoo Finance· 1 year agoAmgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. Amgen...